BPC-157 Peptide Research Guide
For laboratory and research use only. Not for human or veterinary use. This page summarizes published scientific literature for educational purposes only.
BPC-157 is one of the most-discussed peptides in tissue-repair research. This guide covers what the BPC-157 peptide is, the mechanisms studied in the literature, the important caveat that its evidence base is largely preclinical, and how laboratories handle and reconstitute it. Browse the full research compound catalog for related compounds.
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). It corresponds to a partial sequence of a larger protective protein originally identified in gastric juice. Unlike the incretin peptides, it is not a receptor agonist for a metabolic target; it is studied for its reported roles in tissue protection and repair pathways.
Mechanism studied in research
In the published preclinical literature, BPC-157 is described as interacting with several repair-related pathways. The most frequently cited is its apparent effect on angiogenesis — the formation of new blood vessels — reported in animal and cell models to involve the VEGFR2 receptor and the nitric-oxide (NO) system. Researchers have also examined its reported effects on the gastrointestinal mucosa, and on tendon, ligament, muscle, and bone healing in rodent injury models. These are mechanistic findings from experimental models, not established human outcomes.
What the research literature reports
An important distinction sets BPC-157 apart from compounds like semaglutide or tirzepatide: its evidence base is predominantly preclinical and animal-model research. Much of the published work originates from a single research group (Sikiric et al., University of Zagreb) and appears in journals such as Current Pharmaceutical Design and Current Medicinal Chemistry. Robust, large-scale human clinical trials are lacking, and the compound is not an approved drug in the United States. Any description of its effects should be read as a summary of laboratory and animal research only. Researchers should consult primary sources on PubMed.
Note: the mechanisms above summarize published preclinical research and are not health claims. The research-grade material supplied here is for laboratory use only.
Laboratory handling
Research-grade BPC-157 ships as a lyophilized (freeze-dried) powder and is characterized by HPLC, with a Certificate of Analysis available on our Lab Results page. It is reconstituted with sterile bacteriostatic water before use; our reconstitution calculator returns the exact diluent volume for a given vial. You can view research-grade BPC-157 in our catalog; bacteriostatic water is included free with every order.
Frequently asked questions
Is BPC-157 a peptide?
Yes — BPC-157 is a synthetic pentadecapeptide, meaning a peptide made of 15 amino acids. It is derived from a partial sequence of a protein found in gastric juice.
Is there human clinical trial data on BPC-157?
The published evidence is predominantly preclinical and from animal models. Large-scale human clinical trials are lacking, and BPC-157 is not an approved drug. It is supplied strictly as a research material.
How is research-grade BPC-157 characterized?
By HPLC analysis with a third-party Certificate of Analysis documenting identity and purity, typically at ≥99%.
What diluent is used to reconstitute it?
Sterile bacteriostatic water; the exact volume depends on the vial’s milligram content and the target concentration, which our reconstitution calculator computes.
Disclaimer: Research-grade BPC-157 supplied by MyGLP1Store is strictly for laboratory and in-vitro research. It is not an approved drug, not a supplement, and not for human or veterinary use.